^
    2years
    Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation. (PubMed, Sci Rep)
    We found that certain mutations affected the c-KIT phosphorylation status and cell proliferation. This suggests that heterogeneity among the population of tumor cells exists in MCTs, and that the dominant clones of this heterogeneity may contribute to the subsequent tumor cell growth.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT exon 8 mutation
    almost3years
    The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia. (PubMed, Clin Lymphoma Myeloma Leuk)
    According to our study, the results may suggest c-KIT mutation as a poor risk factor in pediatric CBF-AML.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT D816V • KIT exon 17 mutation • KIT exon 8 mutation
    over4years
    [VIRTUAL] Driver mutations in pediatric core binding factor acute myeloid leukemia (ESHG 2020)
    Mutational profiling revealed characteristic differences in spectrum and frequency of somatic mutations in patients with t(8;21) and inv(16). Novel mutations, which may be involved in leukemia development, were identified. The work was supported by the Russian Science Foundation (grant # 18−15-00398).
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • ASXL1 (ASXL Transcriptional Regulator 1) • CBL (Cbl proto-oncogene) • KDM6A (Lysine Demethylase 6A)
    |
    KRAS mutation • NRAS mutation • KIT mutation • CBL mutation • MLL mutation • FLT3 mutation + MLL mutation • KIT exon 8 mutation